Exelixis Inc (EXEL) Stock AnalysisEXELExelixis Inc

Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Exelixis Inc is a good buy right now due to its current price of $59.86, which is below the analyst price targets of $51 and $54, indicating potential upside. The stock has shown strong performance with a year-to-date change of +37.36% and a 1-year change of +55.72%. However, the RSI is at 73.058, suggesting it may be overbought, which is a risk to consider.

10 analysts cover EXEL: 6 rate it Buy, 4 Hold and 0 Sell. The average price target is 44.09.